MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Income Overview
Net Income
-$47,835,431
EPS
-$0.79
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
General and administrative expenses
1,320,002
573,539
838,472
386,951
Research and development expenses
444,674
467,797
1,296,209
759,525
Total operating costs
1,764,676
1,041,336
2,134,681
1,146,476
Interest income
46,176
51,644
73,488
44,182
Interest expense
3,028
1,255
-
-
Total other income, net
43,148
50,389
-
-
Net loss
-1,721,528
-990,947
-2,061,193
-1,102,294
Deemed dividend
46,113,903
-
-
-
Net loss attributable to common stockholders
-47,835,431
-
-
-
Basic EPS
-0.79
-0.03
-0.06
-0.03
Diluted EPS
-0.79
-0.03
-0.06
-0.03
Basic Average Shares
60,837,460
34,380,971
34,440,634
32,398,906
Diluted Average Shares
60,837,460
34,380,971
34,440,634
32,398,906
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
TELO Income Statement Sankey Diagram
Sankey diagram visualizing TELO income statement for the period
Net loss
attributable to common...
-$47,835,431
Interest income
$46,176
(3290.31%↑ Y/Y)
Deemed dividend
$46,113,903
Net loss
-$1,721,528
(66.04%↑ Y/Y)
Total other income,
net
$43,148
Interest expense
$3,028
(125.63%↑ Y/Y)
Total operating costs
$1,764,676
(-65.19%↓ Y/Y)
General and
administrative expenses
$1,320,002
(-73.74%↓ Y/Y)
Research and development
expenses
$444,674
(938.01%↑ Y/Y)
Buy us a coffee
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)